Editas Medicine

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.
The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Type
Public
HQ
Cambridge, US
Founded
2013
Employees
75 (est)+16%
Editas Medicine was founded in 2013 and is headquartered in Cambridge, US

Key People at Editas Medicine

Deborah Palestrant

Deborah Palestrant

Senior Director, Business Development & Strategy
Alexandra Glucksmann

Alexandra Glucksmann

COO
George Church

George Church

Co - Founder
Kevin Bitterman

Kevin Bitterman

Interim President
Jennifer A. Doudna

Jennifer A. Doudna

Co - Founder
J. Keith Joung

J. Keith Joung

Co - Founder

Editas Medicine Locations

Cambridge, US

Editas Medicine Metrics

Editas Medicine Summary

Market capitalization

$566 M

Closing share price

$16
Editas Medicine's latest market capitalization is $566 M.

Editas Medicine Market Value History

53% of current employees of Editas Medicine are female and 47% are male.

Editas Medicine News

Editas Medicine Company Life